ProMIS Neurosciences Releases Second Quarter Update

ProMIS Neurosciences (TSX:PMN) provided a corporate update to shareholders for the second quarter of 2017.
As quoted in the press release:

Commenting on the update, ProMIS Executive Chairman Eugene Williams stated: “We are pleased with the continued progress at ProMIS and remain confident that our monoclonal antibody programs focused on selectively targeting the toxic, prion-like forms of Amyloid beta may lead to best in class therapies and significant long-term value creation”.

Click here to read the full press release.

Source: www.newswire.ca